Insider Buying: Perspective Therapeutics, Inc. (NYSE:CATX) CFO Acquires 12,829 Shares of Stock

Perspective Therapeutics, Inc. (NYSE:CATX) CFO Jonathan Robert Hunt acquired 12,829 shares of Perspective Therapeutics stock in a transaction on Monday, November 25th. The shares were purchased at an average price of $3.82 per share, for a total transaction of $49,006.78. Following the completion of the purchase, the chief financial officer now directly owns 48,800 shares of the company’s stock, valued at approximately $186,416. This represents a 35.66 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Perspective Therapeutics Stock Down 6.4 %

NYSE:CATX opened at $4.12 on Thursday. Perspective Therapeutics, Inc. has a one year low of $2.28 and a one year high of $19.05. The stock’s 50-day simple moving average is $10.96.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The company had revenue of $0.37 million for the quarter. On average, equities analysts predict that Perspective Therapeutics, Inc. will post -0.87 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CATX. nVerses Capital LLC bought a new position in shares of Perspective Therapeutics in the third quarter worth $57,000. US Bancorp DE lifted its holdings in Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after purchasing an additional 3,866 shares in the last quarter. Victory Capital Management Inc. bought a new position in Perspective Therapeutics in the 2nd quarter worth about $117,000. Point72 DIFC Ltd purchased a new position in Perspective Therapeutics during the 2nd quarter valued at about $118,000. Finally, Intech Investment Management LLC bought a new stake in shares of Perspective Therapeutics during the third quarter valued at about $137,000. Institutional investors own 54.66% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Wedbush reiterated an “outperform” rating and set a $11.00 price target (down previously from $20.00) on shares of Perspective Therapeutics in a research report on Thursday, November 21st. Bank of America downgraded Perspective Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the company from $24.00 to $5.00 in a report on Monday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Oppenheimer dropped their price objective on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, November 22nd. Finally, UBS Group initiated coverage on Perspective Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $20.00 target price on the stock. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Perspective Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $15.14.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.